Investegate announcements from atai Life Sciences, atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai's portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel
Investegate announcements from atai Life Sciences, atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
Investegate announcements from atai Life Sciences, atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai s supply chain
TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health. This new platform company will